CNIO cancer conference: Targeted search for anticancer drugs

Expert Opinion on Investigational Drugs

Volumn 12, Issue 6, 2003, Pages 1039-1044

  Fischer, Peter M ^a  

^a CYCLACEL LTD   (United Kingdom)

Author keywords

Angiogenesis; Apoptosis; Cancer targets; Cell cycle; Hypoxia; Kinase; Metabolism; Warburg effect

Indexed keywords

17 AAG; 17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 2 ANILINO 4 HETEROARYL PYRIMIDINE DERIVATIVE; ALPHA5 INTEGRIN; ANGIOGENESIS INHIBITOR; ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; CASPASE; CHOLINE KINASE; CILENGITIDE; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOCHROME C; HEAT SHOCK PROTEIN 90; HEMICHOLINIUM DERIVATIVE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PORPHYRIN DERIVATIVE; PROTEIN BCL 2; PROTEIN INHIBITOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; PX 478; PYRIMIDINE DERIVATIVE; ROSCOVITINE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER RESEARCH; CELL CYCLE; CELL DEATH; CELL METABOLISM; CELL SURVIVAL; CELL TRANSFORMATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INFUSION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; GLYCOLYSIS; HUMAN; MAXIMUM TOLERATED DOSE; NONHUMAN; SOLID TUMOR; SYMPOSIUM;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS;

EID: 0037671431     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.6.1039     Document Type: Conference Paper

References (22)

1. BRUMMELKAMP TR, BERNARDS R, AGAMI R: Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell (2002) 2:243-247.
2. GARTEL AL, TYNER AL: The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol. Cancer Ther. (2002) 1:639-649.
3. BOROS LG, LEE W-NP, GO VLW: A metabolic hypothesis of cell growth and death in pancreatic cancer. Pancreas (2002) 24:26-33.
4. USUBA T, ISHIBASHI Y, OKAWA Y, HIRAKAWA T, TAKADA K, OHKAWA K: Purification and identification of monoubiquitin-phosphoglycerate mutase B complex from human colorectal cancer tissues. Int. J. Cancer (2001) 94:662-668.
5. PLAS DR, THOMPSON CB: Cell metabolism in the regulation of programmed cell death. Trends Endocrin. Metabol. (2002) 13:75-78.
6. POWIS G, MONTFORT WR: Properties and biological activities of thioredoxins. Ann. Rev. Pharmacol. Toxicol. (2001) 41:261-295.
7. SHAWVER LK, SLAMON D, ULLRICH A: Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell (2002) 1:117-123.
8. AHERNE W, MALONEY A, SHARP S et al.: Discovery of a novel synthetic inhibitor of the Hsp90 molecular chaperone. Proc. Am. Assoc. Cancer Res. (2003) 44:4002 (Abstract).
9. MCCLUE SJ, BLAKE D, CLARKE R et al.: In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer (2002) 102:463-468.
10. LAURENCE V, FAIVRE S, VERA K et al.: Preliminary results of an ongoing Phase I and pharmacokinetic study of CYC202, a novel oral cyclin-dependent kinases inhibitor, in patients with advanced malignancies. Eur. J. Cancer (2002) 38(Suppl.7):49 (Abstract).
11. BENSON C, RAYNAUD F, O'DONNELL A et al.: Pharmacokinetics (PK) of the oral cyclin dependent kinase inhibitor CYC202 (R-roscovitine) in patients with cancer. Proc. Am. Assoc. Cancer Res. (2002) 43:1354 (Abstract).
12. WU SY, MCNAE I, KONTOPIDIS G et al.: Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. Structure (2003) 11:399-410.
13. MCINNES C, ANDREWS MJI, ZHELEVA DI, LANE DP, FISCHER PM: Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit. Curr. Med. Chem. Anticancer Agents (2003) 3:57-69.
14. KNOCKAERT M, GREENGARD P, MEIJER L: Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. (2002) 23:417-425.
15. HERNANDEZ-ALCOCEBA R, SANIGER L, CAMPOS J et al.: Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene (1997) 15:2289-2301.
16. CONEJO-GARCIA A, CAMPOS J, SANCHEZ RM et al.: Choline kinase inhibitory effect and antiproliferative activity of new 1,1',1'-(benzene-1,3,5-triylmethylene)tris[4-[(disubstituted amino]pyridinium] tribromides. Eur. J. Med. Chem. (2003) 38:109-116.
17. ZHOU BB, ELLEDGE SJ: The DNA damage response: putting checkpoints in perspective. Nature (2000) 408:433-439.
18. CHATURVEDI P, ENG WK, ZHU Y et al.: Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene (1999) 18:4047-4054.
19. CHATURVEDI P SUDAKIN V, BOBIAK ML et al.: Chfr regulates a mitotic stress pathway through its RING-finger domain with ubiquitin ligase activity. Cancer Res. (2002) 62:1797-1801.
20. SIDDIQUI-JAIN A, GRAND CL, BEARSS DJ, HURLEY LH: Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc. Natl. Acad. Sci. USA (2002) 99:11593-11598.
21. WARBURG O, GAWEHN K, GEISSLER AW, LORENZ S: On the transformation of embryonal metabolism into cancer metabolism. Hoppe-Seyler's Z. Physiol. Chem. (1960) 2:252-257.
22. ULLRICH A: Molecular targets in cancer therapy and their impact on cancer management. Oncology (2002) 63(Suppl. 1):1-5.